Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis-Reference-Cited by-同舟云学术

Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis

Published:2020-01-27 Issue:2 Volume:22 Page:
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Nøhr-Nielsen Asbjørn,Lange Theis,Forman Julie Lyng,Papathanasiou Theodoros,Foster David J. R.,Upton Richard N.,Bjerrum Ole Jannik,Lund Trine Meldgaard

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-020-0414-y.pdf

Reference36 articles.

1. Rationalizing combination therapies. Nat Med. 2017;23(10):1113–3.

2. Mokhtari RB, Homayouni TS, Baluch N. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43.

3. Ascierto PA, Marincola FM. Combination therapy: the next opportunity and challenge of medicine. J Transl Med. 2011;9(1):115.

4. Bell DSH. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291–300.

5. Navarro J, Curran A. Profile of once-daily darunavir/cobicistat fixeddose combination for the treatment of HIV/AIDS. HIV/AIDS - Res Palliat Care. 2016;8:175–82.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of the Development of Multitarget Molecules against HIV-TB Coinfection Pathogens;Molecules;2023-04-10

2. Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis;Journal of Pharmacokinetics and Pharmacodynamics;2023-01-17